Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
04/08/2021 04/09/2021 04/12/2021 04/13/2021 04/14/2021 Date
12.6(c) 13.76(c) 13.74(c) 13.2(c) 13.24 Last
240 806 442 056 93 736 49 576 8 521 Volume
+14.55% +9.21% -0.15% -3.93% +0.30% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -3,40 M -4,07 M -4,07 M
Net Debt 2020 - - -
P/E ratio 2020 -8,80x
Yield 2020 -
Sales 2021 18,5 M 22,1 M 22,1 M
Net income 2021 8,13 M 9,73 M 9,73 M
Net cash position 2021 14,2  17,0  17,0 
P/E ratio 2021 10,7x
Yield 2021 -
Capitalization 48,9 M 58,3 M 58,5 M
Capi. / Sales 2020 -
EV / Sales 2021 2,64x
Nbr of Employees 17
Free-Float 70,1%
More Financials
Company
Theranexus specializes in the research and development of therapeutic products for the treatment of diseases affecting the central nervous system. At the end of 2019, the group had a portfolio of 3 products in clinical development phase, including 1 in phase II (THN102; treatment of narcolepsy-related sleep-wake disorders and Parkinson's disease) and 2 in phase I (THN101 for the treatment of neuropathic pain and... 
More about the company
Notations Surperformance© of Theranexus
Trading Rating : Investor Rating : -
More Ratings
All news about THERANEXUS
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
PU
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
AN
04/07THERANEXUS  : Annual results
CO
03/10THERANEXUS  : Extends the capacities of neurolead, its asset screening platform,..
AQ
03/09THERANEXUS  : Theranexus extends the capabilities of neurolead, its active agent..
AN
01/22THERANEXUS  : presents an update on the progress of its main programs and announ..
PU
01/19THERANEXUS  : Provides an update on the progress of its main programs and announ..
AQ
01/18THERANEXUS  : Theranexus presents an update on the progress of its main programs..
AN
01/18THERANEXUS  : 4th quarter earnings
CO
2020THERANEXUS  : Publishes its 2021 financial agenda
AQ
2020THERANEXUS  : announces its financial calendar for 2021
PU
2020THERANEXUS  : Theranexus announces its financial calendar for 2021
AN
2020THERANEXUS  : Provisional calendar
CO
2020THERANEXUS THE  : Lyon neuroscience research center and CERMEP announce the crea..
AQ
2020THERANEXUS  : Creates Drug Development JV; Stock Down4%
MT
More news
News in other languages on THERANEXUS
04/08THERANEXUS  : Présentation investisseurs résultats annuels 2020 Portzamparc (08/..
04/08STOCK MARKET PARIS : Moral toujours au beau fixe sur les marchés
04/08Les valeurs à suivre aujourd'hui à la Bourse de Paris Jeudi 8 avril 2021
04/08EN DIRECT DES MARCHES  : Vinci, Alstom, Danone, Europcar, Prosus, KPN, Toshiba, ..
04/08THERANEXUS  : A suivre aujourd'hui
More news
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,50 €
Last Close Price 13,20 €
Spread / Highest target 173%
Spread / Average Target 93,2%
Spread / Lowest Target 51,5%
EPS Revisions
Managers and Directors
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial & Administrative Officer
Mathieu Bernard Mari Charveriat Director, Chief Scientific Officer & Deputy CEO
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-29.22%58
GILEAD SCIENCES, INC.10.99%81 411
VERTEX PHARMACEUTICALS INCORPORATED-8.63%55 284
WUXI APPTEC CO., LTD.-0.16%49 513
REGENERON PHARMACEUTICALS, INC.-2.13%49 239
BIONTECH SE59.03%29 350